CNSide Diagnostics
Healthcare Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Cnside Diagnostics Llc's Lab, Houston, T...Website
www.cnside-dx.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About CNSide Diagnostics
CNSide Diagnostics, LLC is dedicated to developing and commercializing proprietary clinical diagnostic laboratory assays, specifically the CNSide CSF assay, designed for patients with Leptomeningeal Metastases. This innovative platform provides healthcare providers with valuable insights through the quantitative analysis and molecular characterization of tumor cells, enhancing patient care and treatment decisions. The company operates a CLIA-registered lab in Houston, Texas, focusing on improving patient outcomes with cutting-edge diagnostics. Their mission is to revolutionize the management of patients suffering from Leptomeningeal Metastases by delivering sensitive and definitive diagnostic solutions.Explore more
Popular SearchesCNSide Diagnostics LLCSIC Code 80,807NAICS Code 62,621Show moreCNSide Diagnostics Org Chart
AB
Interim Chief Marketing Officer, Ad
AS
Finance Chief Financial Officer & Vice Presid...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CNSide Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if CNSide Diagnostics is spiking on competitors!
Earning: See what the market has to say on CNSide Diagnostics recently announced quarterly report
CNSide Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when CNSide Diagnostics launches new products
Click to see if CNSide Diagnostics had a recent Job posting/layoffs
Check if CNSide Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once CNSide Diagnostics has new funding data
Congratulate Masked Content for being promoted to Masked Content at CNSide Diagnostics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
CNSide Diagnostics is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
CNSide Diagnostics is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about CNSide Diagnostics.
CNSide Diagnostics Tech Stack
CNSide Diagnostics News & Media
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
CAP accreditation, widely recognized as the gold standard in laboratory quality assurance, complements CNSide Diagnostics' existing CLIA certification and further supports U.S. commercial launch of the CNSide® CSF Assay Platform CAP accreditation, widely recognized as the gold standard in laboratory quality assurance, complements CNSide Diagnostics' existing CLIA certification and further supports U.S. commercial launch of the CNSide® CSF Assay PlatformPlus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40%Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
Partnership to deliver a novel AI-native integrated CNS oncology platformPlus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces financial results for the first quarter ended March 31, 2026 and provides an overview of recent and upcoming business highlights.
Read more news
Top Healthcare Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding CNSide Diagnostics
Sign Up For FreeTo access detailed company insights
CNSide Diagnostics, LLC is dedicated to developing and commercializing proprietary clinical diagnostic laboratory assays, specifically the CNSide CSF assay, designed for patients with Leptomeningeal Metastases. This innovative platform provides healthcare providers with valuable insights through the quantitative analysis and molecular characterizat... Read More
